The use of isotretinoin increases the risk of inflammatory bowel disease. A narrative review
Fuente:
Redalyc
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artículo científico |
| Langue: | en |
| Publié: |
Hospital San Pedro
2024
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1876463394851127296 |
|---|---|
| author | Manuel Enrique Duarte-Arias |
| author_facet | Manuel Enrique Duarte-Arias |
| contents | The use of isotretinoin increases the risk of inflammatory bowel disease. A narrative review Manuel Enrique Duarte-Arias Juan Esteban Ospina-Gómez María Paula Saavedra-Díaz Medicina Isotretinioin Acne vulgaris Inflammatory bowel disease Introduction: Acne vulgaris represents a prevalent dermatological condition capable of exerting a profound impact on an individual's quality of life. Isotretinoin, despite its wellestablished status as a highly effective remedy for severe acne, concerns surrounding the potential linkage with inflammatory bowel disease (IBD) have led to inquiries about its association. Objective: The primary objective of this review is to critically assess the existing body of evidence pertaining to the efficacy and safety of isotretinoin, with a particular emphasis on its association with IBD. Methods: A literature review was undertaken to examine the utilization of isotretinoin in the management of acne and to evaluate the subsequent risk of inflammatory bowel disease, aiming to determine the relevance of considering this factor when utilizing this treatment. Conclusions: Isotretinoin is widely recognized as the most effective therapeutic approach to treat acne. This compound competently addresses all underlying factors contributing to acne pathogenesis. Over time, extensive deliberation has arisen concerning concerns related to its potential correlation with the onset of IBD. The currently available evidence conveys a paucity of substantial scientific support for a causal relationship between the use of isotretinoin and the development of IBD. 2024 artículo científico 2695-5075 https://www.redalyc.org/articulo.oa?id=692082773006 https://www.redalyc.org/journal/6920/692082773006/ https://www.redalyc.org/journal/6920/692082773006/html/ https://www.redalyc.org/journal/6920/692082773006/692082773006.epub https://www.redalyc.org/journal/6920/692082773006/movil 10.53986/ibjm.2024.0021 en http://www.redalyc.org/revista.oa?id=6920 Iberoamerican Journal of Medicine application/pdf Hospital San Pedro Iberoamerican Journal of Medicine (España) Num.4 Vol.6 |
| format | Artículo científico |
| id | redalyc_692082773006 |
| institution | Redalyc |
| language | en |
| publishDate | 2024 |
| publisher | Hospital San Pedro |
| spellingShingle | The use of isotretinoin increases the risk of inflammatory bowel disease. A narrative review Manuel Enrique Duarte-Arias Medicina Isotretinioin Acne vulgaris Inflammatory bowel disease The use of isotretinoin increases the risk of inflammatory bowel disease. A narrative review Manuel Enrique Duarte-Arias Juan Esteban Ospina-Gómez María Paula Saavedra-Díaz Medicina Isotretinioin Acne vulgaris Inflammatory bowel disease Introduction: Acne vulgaris represents a prevalent dermatological condition capable of exerting a profound impact on an individual's quality of life. Isotretinoin, despite its wellestablished status as a highly effective remedy for severe acne, concerns surrounding the potential linkage with inflammatory bowel disease (IBD) have led to inquiries about its association. Objective: The primary objective of this review is to critically assess the existing body of evidence pertaining to the efficacy and safety of isotretinoin, with a particular emphasis on its association with IBD. Methods: A literature review was undertaken to examine the utilization of isotretinoin in the management of acne and to evaluate the subsequent risk of inflammatory bowel disease, aiming to determine the relevance of considering this factor when utilizing this treatment. Conclusions: Isotretinoin is widely recognized as the most effective therapeutic approach to treat acne. This compound competently addresses all underlying factors contributing to acne pathogenesis. Over time, extensive deliberation has arisen concerning concerns related to its potential correlation with the onset of IBD. The currently available evidence conveys a paucity of substantial scientific support for a causal relationship between the use of isotretinoin and the development of IBD. 2024 artículo científico 2695-5075 https://www.redalyc.org/articulo.oa?id=692082773006 https://www.redalyc.org/journal/6920/692082773006/ https://www.redalyc.org/journal/6920/692082773006/html/ https://www.redalyc.org/journal/6920/692082773006/692082773006.epub https://www.redalyc.org/journal/6920/692082773006/movil 10.53986/ibjm.2024.0021 en http://www.redalyc.org/revista.oa?id=6920 Iberoamerican Journal of Medicine application/pdf Hospital San Pedro Iberoamerican Journal of Medicine (España) Num.4 Vol.6 |
| title | The use of isotretinoin increases the risk of inflammatory bowel disease. A narrative review |
| topic | Medicina Isotretinioin Acne vulgaris Inflammatory bowel disease |
| url | https://www.redalyc.org/articulo.oa?id=692082773006 https://www.redalyc.org/journal/6920/692082773006/ https://www.redalyc.org/journal/6920/692082773006/html/ https://www.redalyc.org/journal/6920/692082773006/692082773006.epub https://www.redalyc.org/journal/6920/692082773006/movil |